Manages elevated serum phosphorus levels. ANDA 202329, held by Alkem Labs Ltd. Lanthanum Carbonate.
As of Nov 16, 2026, ANDA 202329 (Lanthanum Carbonate), held by Alkem Labs Ltd, was first approved by FDA on Mar 13, 2025, with 0 approved supplements and 0 published complete response letters.
Lanthanum carbonate is a phosphate binder indicated to reduce serum phosphate in patients with end-stage renal disease (ESRD). Management of elevated serum phosphorus levels in patients with ESRD usually includes all of the following: reduction in dietary intake of phosphate, removal of phosphate by dialysis, and reduction of intestinal phosphate absorption with phosphate binders.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Mar 13, 2025 | Original application | Approved | None posted |
| Lanthanum CarbonateEQ 500MG BASE · tablet, chewable;oral | Lanthanum Carbonate | Rx |
| Lanthanum CarbonateEQ 750MG BASE · tablet, chewable;oral | Lanthanum Carbonate | Rx |
| Lanthanum CarbonateEQ 1GM BASE · tablet, chewable;oral | Lanthanum Carbonate | Rx |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters